Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response Journal Article
| Authors: | Vaccarello, L.; Rubin, S. C.; Vlamis, V.; Wong, G.; Jones, W. B.; Lewis, J. L.; Hoskins, W. J. |
| Article Title: | Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response |
| Abstract: | Recurrent ovarian cancer after negative findings at second-look laparotomy is common. A retrospective review of 57 patients who developed recurrent tumor after a negative second-look laparotomy was undertaken to evaluate treatment efficacy and prognostic factors. All patients received primary platinum-based chemotherapy. Recurrences occurred in the abdomen or pelvis (40 patients), lymph nodes (7), liver (4), lungs (3), and vagina (3). Recurrent disease was diagnosed at a mean interval of 20 months after second- look surgery. of the 38 patients who underwent laparotomy for recurrence, 36 (95%) had >0.5 cm disease. After cytoreductive surgery 14 patients (37%) were left with minimal (<0.5 cm) residual disease. Intestinal resection or bypass was performed on 10/38 patients (26%) with one requiring a colostomy. There was no operative mortality and one complication (small bowel obstruction). Treatment after recurrence consisted of platinum-based chemotherapy (88%), with the remaining patients receiving irradiation or hormonal therapy. At a mean follow-up from recurrence for the entire group of 20 months, 18/38 (47%) explored patients are alive. All 19 patients who were not explored died with a median survival time from recurrence of 9 months. Patients who underwent a laparotomy and patients with <0.5 cm residual disease had a significant survival advantage (P < 0.0001). Initial stage, grade, disease-free interval, and disease found at laparotomy did not influence survival. Recurrent ovarian carcinoma after platinum-based chemotherapy is associated with a grave prognosis when the patient is deemed inoperable or when distant metastasis are found. Patients with disease reduced to <0.5 cm showed a significant survival advantage. © 1995 Academic Press. |
| Journal Title: | Gynecologic Oncology |
| Volume: | 57 |
| Issue: | 1 |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 1995-04-01 |
| Start Page: | 61 |
| End Page: | 65 |
| Language: | English |
| DOI: | 10.1006/gyno.1995.1099 |
| PROVIDER: | scopus |
| PUBMED: | 7705701 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 28 August 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work